Shared insight on the optimal use of RET inhibitor therapy in select patients with RET-rearranged radioiodine-refractory differentiated thyroid cancer.
Key opinion leaders in the field of renal cell carcinoma management discuss the advent of combination immunotherapy in patients with metastatic disease.